BND Bio Drug Store

BND Bio is a South Korean biotechnology company focused on developing innovative therapies for cancer by targeting metabolic and epigenetic pathways. The company's lead candidate, BND-67, is a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) currently being evaluated for the treatment of acute myeloid leukemia and various solid tumors. BND Bio leverages its proprietary platform to identify novel targets that regulate cancer cell survival and resistance. The firm aims to address high unmet medical needs in oncology through precision medicine approaches. Founded by industry veterans, the company focuses on the intersection of metabolic reprogramming and epigenetic modification to overcome drug resistance in cancer.